ACHE and Alzheimer disease: Compared with the AD group, the high-dose KSG group significantly inhibited hippocampal AChE activity (#p < 0.05), and the low-, medium-, and high-dose KSG groups significantly increased ACh levels (#p < 0.05), exhibiting a dose-dependent trend.